1.Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.Lancet. 2009;373:1275–1281.
2.Symplicity HTNI, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN–2 Trial): a randomised controlled trial.Lancet. 2010;376:1903–1909.
3.Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension.N Engl J Med. 2014;370:1393–1401.
4.Kario K, Ogawa H, Okumura K, et al. SYMPLICITY HTN-Japan - First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients. Circ J. 2015;79:1222–1229.
5.Jannetta PJ, Gendell HM. Clinical observations on etiology of essential hypertension.Surg Forum. 1979;30:431–432.
6.Page IH, Heuer GJ. A Surgical Treatment of Essential Hypertension.J Clin Invest. 1935;14:22–26.
7.Grimson KS. Total Thoracic and Partial to Total Lumbar Sympathectomy and Celiac Ganglionectomy in the Treatment of Hypertension.Ann Surg. 1941;114:753–775.
8.Jordan J. Device-Based Approaches for the Treatment of Arterial Hypertension. Curr Hypertens Rep. 2017;19:59.
9.Yerasi C, Baker NC, Jonnalagadda AK, et al. Assessment of hypertension control and clinical course of patients excluded from the SYMPLICITY HTN–3 trial.J Am Soc Hypertens. 2015;9:959–965.
10.Epstein M, de Marchena E. Is the failure of SYMPLICITY HTN–3 trial to meet its efficacy endpoint the “end of the road” for renal denervation?J Am Soc Hypertens. 2015;9:140–149.
11.Bohm M, Mahfoud F, Ukena C, et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.Hypertension. 2015;65:766–774.
12.Sakakura K, Ladich E, Cheng Q, et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014;64:635–643.
13.Tzafriri AR, Mahfoud F, Keating JH,et al. Innervation patterns may limit response to endovascular renal denervation.J Am Coll Cardiol. 2014;64:1079–1087.
14.Lu J, Wang Z, Zhou T, et al. Selective proximal renal denervation guided by autonomic responses evoked via high-frequency stimulation in a preclinical canine model. Circ Cardiovasc Interv. 2015;8.
15.Daniels J, Gray R, Hills RK, et al. Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: a randomized controlled trial.JAMA. 2009;302:955–961.
16.Schlaich MP, Lambert E, Kaye DM, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension. 2004;43:169–175.
17.Streitparth F, Walter A, Stolzenburg N, et al. MR-guided periarterial ethanol injection for renal sympathetic denervation: a feasibility study in pigs.Cardiovasc Intervent Radiol. 2013;36:791–796.
18.Fischell TA, Vega F, Raju N, et al. Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model.EuroIntervention. 2013;9:140–147.
19.Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.Lancet. 2017;390:2160–2170.
20.Wang Q, Guo R, Rong S, et al. Noninvasive renal sympathetic denervation by extracorporeal high-intensity focused ultrasound in a pre-clinical canine model. J Am Coll Cardiol. 2013;61:2185–2192.